U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. Drug Supply Chain Security Act Implementation: Identification of Suspect Product and Notification Guidance for Industry
  1. Search for FDA Guidance Documents

GUIDANCE DOCUMENT

Drug Supply Chain Security Act Implementation: Identification of Suspect Product and Notification Guidance for Industry June 2021

Download the Final Guidance Document Read the Federal Register Notice
Final
Docket Number:
FDA-2014-D-0609
Issued by:
Guidance Issuing Office
Office of Inspections and Investigations
Center for Biologics Evaluation and Research
Center for Drug Evaluation and Research

This guidance is intended to aid trading partners3,4 (manufacturers, repackagers, wholesale distributors, and dispensers) in identifying a suspect product as defined at section 581(21) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 360eee(21)) and terminating notifications. It does not establish any rights for any person and, with the exception of section IV.B, it is not binding on FDA or the public. With respect to section IV.B, section 582 of the FD&C Act gives FDA authority to issue binding guidance on the process for terminating notifications of illegitimate product. Specifically, section 582(h)(2)(A) states that FDA "shall issue a guidance document to aid trading partners in the identification of a suspect product and notification termination. Such guidance document shall . . . set forth the process by which manufacturers, repackagers, wholesale distributors, and dispensers shall terminate notifications in consultation with the Secretary regarding illegitimate product . . . ."

Submit Comments

Submit Comments Online

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2014-D-0609.

Back to Top